Johnson & Johnson (JNJ) said Wednesday that it has received approval from the US Food and Drug Administration for Imaavy, a treatment for generalized myasthenia gravis.
The treatment, also known as nipocalimab-aahu, has the potential to provide lasting disease control in adults and pediatric patients aged 12 and up who test positive for anti-acetylcholine receptor or anti-muscle-specific kinase antibody, the company said.
The company said applications for the approval of nipocalimab are being reviewed by regulatory authorities globally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.